Intellia Therapeutics (NTLA) PT Lowered to $108 at Wedbush, Following Strategic Business Update
Tweet Send to a Friend
Wedbush analyst David Nierengarten lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $108.00 (from $123.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
